Corcept Therapeutics Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Corcept is publicly owned but remains meaningfully founder-influenced because Joseph Belanoff leads the company and owns a material stake. G. Leonard Baker Jr. chairs the board and also holds a sizable position, aligning wealth while increasing the need for rigorous independent challenge. We see this as the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Public shareholders own Corcept, while founder and chief executive Joseph Belanoff owns 6.1% and longtime director G. Leonard Baker Jr. owns 5.3%. Joseph Belanoff leads the enterprise and G. Leonard Baker Jr. provides board or owner oversight, so formal percentages must be read beside board independence, voting rights and contractual authority. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. A governance premium is earned only when independent oversight reduces agency risk and protects capital through a full cycle. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would tie executive rewards to per-share value, balance-sheet resilience and clearly measured strategic outcomes. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
BlackRock, Vanguard, Ingalls & Snyder and Renaissance are disclosed large owners. Their mix of passive, value and quantitative capital can support liquidity, but a regulatory event can still overwhelm normal stewardship channels. We see this as the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The institutional register lists BlackRock, The Vanguard Group, Ingalls & Snyder, Renaissance Technologies at 10.7%, 8.9%, 7.6%, 5.4%. These stakes influence elections, liquidity and engagement, but they do not guarantee a common view on strategy or risk. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. Stable institutions can reduce financing uncertainty, but concentration cannot substitute for durable operating results or engaged directors. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
Korlym funds the enterprise, while Lifyorli starts a second commercial story and the pipeline supplies future optionality. Portfolio management must distinguish reusable cortisol science from indication-specific development risk. We see this as the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes Korlym, Lifyorli, relacorilant, dazucorilant, miricorilant and exicorilant. Each identity needs a defined customer promise and economic role, with shared capabilities producing measurable benefits instead of administrative complexity. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. A portfolio premium requires evidence that customer trust, technical know-how or distribution produces stronger retention and margins. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Recordati and Xeris compete directly in Cushing syndrome, while larger oncology companies compete for ovarian-cancer treatment share and commercial attention. Corcept must translate mechanistic differentiation into clinical adoption. We see this as the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is 2025 revenue of $761.4 million, net income of $99.7 million and 730 employees, followed by second-quarter 2026 revenue of $256.1 million and a higher full-year revenue outlook of $1.1 billion to $1.2 billion. We test competitive strength through pricing, retention, market share, unit economics and return on invested capital rather than broad claims about addressable markets. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. A competitive premium should follow sustainable cash economics and reinvestment opportunity, not one favorable period or a temporary shortage. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
Corcept has avoided corporate acquisitions, making internal research the central capital-allocation engine. That simplicity clarifies accountability because management cannot blame integration when a program misses its clinical or regulatory objective. We see this as the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because corcept funds clinical trials, commercial launches and internal discovery from operating cash and investments while also repurchasing shares. We expect post-deal scorecards to compare promised economics with retention, margins, cash conversion and financing costs. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. Deal-driven growth warrants a premium only when acquired cash flows exceed financing, integration and opportunity costs under conservative assumptions. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
No merger or spinoff explains current economics; the key structural transition is from a single-product endocrine company to a two-franchise commercial biotechnology platform. That shift increases operating complexity even without a transaction. We see this as the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Corcept has not relied on a transformative merger or spinoff. Its value has been built through internally directed cortisol-modulation research, clinical development, regulatory filings and commercialization. The absence of major acquisitions makes pipeline selection, trial design and regulatory execution more important than integration skill, while the 2026 Lifyorli approval created a second commercial franchise. Today's segments, leverage, ownership rights and strategic choices are direct consequences of those structural decisions. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. Structural change creates value only when accountability, focus or cash generation improves after tax, financing and integration costs. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership History
Ownership History Analysis
Founder continuity created deep scientific focus and patient capital. The same continuity can become a weakness if regulatory feedback is discounted, so ownership quality depends on independent scientific and commercial review. We see this as the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is a founder-led endocrine biotechnology company that converted one cortisol antagonist into a profitable franchise and is now attempting to broaden into oncology and additional diseases. We assign heritage value only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether the governing body challenges management when strategic ambition conflicts with owner returns. Disclosure should make tradeoffs visible instead of forcing stakeholders to infer them from headline results.The downside case is concrete: product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We do not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to leadership. A credible plan should specify triggers for reducing spending, leverage or complexity.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. Historical success informs judgment but cannot be capitalized indefinitely when leadership, technology or industry structure changes. Investors or private owners should compare implied expectations with achievable cash returns and include weaker demand, higher funding costs and execution delays in scenario analysis.We would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. Our view is that Corcept Therapeutics deserves confidence only when leadership demonstrates measurable value creation after all operating, financing, dilution and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership Explained
Corcept Therapeutics operates under this ownership structure: Public shareholders own Corcept, while founder and chief executive Joseph Belanoff owns 6.1% and longtime director G. Leonard Baker Jr. owns 5.3%. Joseph Belanoff leads the enterprise and G. Leonard Baker Jr. provides board or owner oversight. We treat voting authority, board composition and incentive design as more informative than a shareholder list alone because they determine who can change strategy, approve transactions and set risk tolerance.The operating model is a founder-led biotechnology company commercializing cortisol-modulating medicines in endocrinology and oncology while advancing a focused pipeline. Important commercial identities include Korlym, Lifyorli, relacorilant, dazucorilant, miricorilant and exicorilant. We see value when these businesses share technology, distribution, procurement or customer insight without weakening local accountability. Portfolio breadth deserves a premium only if shared ownership improves retention, margins and reinvestment returns.The latest annual record includes 2025 revenue of $761.4 million, net income of $99.7 million and 730 employees, followed by second-quarter 2026 revenue of $256.1 million and a higher full-year revenue outlook of $1.1 billion to $1.2 billion. We use the annual period as the clean scale reference and then incorporate current 2026 developments where they alter ownership, governance or earnings power. Quarterly results can still be distorted by seasonality, transaction timing, launch costs, restructuring charges or volatile end markets.Corcept funds clinical trials, commercial launches and internal discovery from operating cash and investments while also repurchasing shares. Our view is that capital allocation is the practical expression of ownership. Management and directors should compare each acquisition, repurchase, development program or restructuring decision with debt reduction and retained liquidity, then report whether actual returns matched the original underwriting.
Ownership shapes disclosure, financing flexibility and accountability at Corcept Therapeutics. Public shareholders own Corcept, while founder and chief executive Joseph Belanoff owns 6.1% and longtime director G. Leonard Baker Jr. owns 5.3%. We expect the controlling parties and directors to convert that authority into durable per-share or sponsor value rather than treating revenue growth, asset count or transaction volume as ends in themselves.The principal downside exposures are product concentration, patent challenges, regulatory setbacks, trial failure, launch execution, reimbursement, safety findings and ambitious commercial spending can produce severe valuation changes. We would monitor leading operating indicators that reveal whether the franchise is strengthening before reported earnings fully show the change. Balance-sheet resilience belongs inside ownership analysis because it preserves strategic choice when demand, regulation or capital markets become less favorable.At an August 2026 equity value of $14.52 billion, investors capitalize substantial success for Lifyorli and the broader relacorilant opportunity beyond the current revenue base. That benchmark raises the hurdle for new investment and makes scenario discipline essential. We would compare management's implied expectations with conservative cash returns after financing, integration, stock compensation and restructuring costs rather than relying on adjusted profit alone.We would protect launch quality, demand indication-level return forecasts and preserve enough liquidity to fund confirmatory work if regulators require more evidence. This discipline affects investors, employees, customers, suppliers and creditors because it determines service continuity, employment capacity and financial resilience. We see high-quality ownership only when authority produces transparent decisions, measurable accountability and repeatable cash economics.